# A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

> **NCT02203422** · PHASE3 · WITHDRAWN · sponsor: **Shandong University**

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Cyclosporin A
- **DRUG:** rhTPO

## Key facts

- **NCT ID:** NCT02203422
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No eligible patient was enrolled.
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203422, "A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02203422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*